Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ifetroban - Cumberland Pharmaceuticals

Next Previous
X
Search
Drug Profile

Ifetroban - Cumberland Pharmaceuticals

Alternative Names: BMS 18029; BMS 180291; BMS 180291A; BMS-180291-02; Boxaban; CPI 211; Dyscorban; Hepatoren; Portaban; Vasculan

Latest Information Update: 09 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer Bristol-Myers Squibb; Cumberland Pharmaceuticals; Vanderbilt-Ingram Cancer Center
  • Class Antiasthmatics; Antifibrotics; Antihypertensives; Antineoplastics; Antiplatelets; Heterocyclic bicyclo compounds; Oxazoles; Skin disorder therapies; Small molecules
  • Mechanism of Action Thromboxane A2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Asthma; Cardiomyopathies; Cardiovascular disorders; Hepatorenal syndrome; Idiopathic pulmonary fibrosis; Portal hypertension; Solid tumours; Systemic scleroderma
  • Preclinical Interstitial lung diseases
  • Discontinued Coronary thrombosis; Peripheral vascular disorders; Thrombosis

Most Recent Events

  • 06 Aug 2024 Cumberland Pharmaceuticals expects to hear back from the US FDA on orphan drug designation and rare pediatric disease designation application for Duchenne Muscular Dystrophy this year
  • 31 Jan 2024 Phase-II clinical trials in Idiopathic pulmonary fibrosis in USA (PO) (NCT05571059)
  • 08 Nov 2023 US FDA approves IND application for Ifetroban in Idiopathic Pulmonary Fibrosis

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top